Wearable Device Detects Missed Cause of High Blood Pressure

A novel wearable device has identified nighttime hormone surges as a previously overlooked cause of high blood pressure, offering a potential breakthrough in diagnosing primary aldosteronism. This condition, characterized by the adrenal glands producing too much aldosterone, often evades detection through standard blood pressure and blood tests. The device monitors hormone levels throughout the night, a period when these crucial surges occur and can significantly impact blood pressure. Primary aldosteronism, also known as Conn's syndrome, is a leading cause of secondary hypertension, meaning it is caused by another medical condition. It is estimated to affect between 5% and 10% of individuals with high blood pressure, yet it is frequently undiagnosed. The current diagnostic methods often involve multiple blood tests taken at specific times, which may not capture the intermittent or nocturnal nature of the hormone overproduction. This can lead to patients being treated for essential hypertension, the most common form of high blood pressure with no identifiable cause, when the underlying issue is primary aldosteronism. The consequences of untreated primary aldosteronism can be severe, including an increased risk of heart attack, stroke, kidney damage, and heart failure, often at a younger age and with greater severity than in patients with essential hypertension. The new wearable technology aims to provide a more continuous and comprehensive picture of a patient's hormonal activity during sleep, a critical window for understanding the condition. By detecting these nighttime hormone surges, clinicians may be able to more accurately identify patients with primary aldosteronism, allowing for timely and targeted treatment. This could lead to better management of blood pressure, reduced cardiovascular risk, and improved long-term health outcomes for a significant number of patients. The research team behind the device is optimistic that this innovation will revolutionize the diagnostic process for this often-hidden cause of hypertension, moving beyond the limitations of current testing protocols. Further clinical trials and validation are expected to follow the initial findings, with the goal of making this diagnostic tool widely available to healthcare providers.